Progyny, Inc. Stock Price, News & Analysis

Progyny (Nasdaq: PGNY) has announced a strategic partnership with ŌURA, a leading smart ring manufacturer, to enhance women's health monitoring and care from preconception through menopause. The collaboration will integrate ŌURA's wearable technology data into Progyny's healthcare ecosystem starting in early 2026.

The partnership aims to provide comprehensive health tracking capabilities, including sleep patterns, cycle insights, cardiovascular health, and stress levels. This data integration will enable earlier risk identification and support various health goals, particularly in fertility planning and menopause management. The initiative will be available to Progyny's client base, including employers and health plans.

Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has secured a new $200 million revolving credit facility maturing on July 1, 2030. The undrawn facility enhances the company's operational and financial flexibility, though there are no immediate plans for its use.

The company anticipates Q2 2025 financial results to exceed previous guidance due to favorable member activity. Revenue, Adjusted net income, and Adjusted EBITDA are expected to surpass the ranges provided in May. Progyny will report detailed Q2 2025 results on August 7, 2025, after market close.

The company maintains its capital priorities, including potential stock repurchases, product portfolio expansion, investments in distribution channels, and strategic acquisitions.

Progyny (NASDAQ: PGNY), a leader in women's health solutions, has announced the addition of pelvic floor therapy to its comprehensive healthcare offerings. The expansion includes partnerships with Origin for in-person and virtual physical therapy, and Hinge Health for digital care solutions.

The initiative addresses a significant healthcare gap, as one in three women experience pelvic floor issues, with 20% requiring surgery. The program aims to provide early intervention and comprehensive care through specialty-trained providers, potentially reducing the $20 billion annual healthcare costs associated with urinary incontinence alone.

Progyny (NASDAQ: PGNY), a leading women's health and family building solutions provider, has joined Amazon's Health Benefits Connector program as its first comprehensive women's health provider. This collaboration enables eligible Amazon customers to discover and enroll in Progyny's fertility, family building, and menopause benefits through their employers or health plans. Progyny currently serves over 530 employers and health plans, reaching more than 6.7 million lives with its clinically integrated care model. The partnership aims to address the issue that nearly 25% of U.S. adults face in understanding their available health benefits. Through Amazon's platform, users can easily verify their Progyny coverage and access personalized support with just a few clicks.

Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has appointed Elizabeth Bierbower to its Board of Directors. Bierbower brings over 30 years of healthcare industry experience, most recently serving as Chairman and CEO of Friday Health Plans. Her extensive background includes senior leadership roles at Humana, where she served as Segment President, President of the Employer Group Segment, and COO of Specialty Benefits division. She also held key positions at Highmark Blue Cross Blue Shield and Coventry Health Care.

Bierbower currently serves on several boards, including Option Care Health, BlueSprig, Quest Analytics, Paradigm Corp., and Point32Health. CEO Pete Anevski highlighted that her expertise will support Progyny's strategy to deliver increased value to members, clients, and shareholders while expanding reach and impact.

[ "Addition of highly experienced healthcare executive with 30+ years of industry expertise", "Strategic board appointment bringing expertise from major health plans like Humana", "Enhanced governance through director with extensive board experience at healthcare companies" ]

Progyny (NASDAQ: PGNY), a leading women's health and family building solutions provider, has strengthened its Medical Advisory Board with two distinguished appointments. Dr. Gloria Richard-Davis from Morehouse School of Medicine and Dr. Whitney Booker from Columbia University join the board, bringing extensive expertise in women's health and reproductive medicine.

Dr. Richard-Davis is double-board certified in OB-GYN and Reproductive Endocrinology and Infertility, with significant experience in menopause care and health equity. Dr. Booker, double-board certified in OB-GYN and Maternal-Fetal Medicine, specializes in high-risk maternal care and prenatal fetal diagnosis, with NIH-funded research focusing on hypertension and cardiovascular disease in pregnancy.

Progyny (NASDAQ: PGNY), a leading provider of women's health and family building solutions, has announced its participation in the upcoming BofA Securities 2025 Health Care Conference. CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat on May 14, 2025, at 3:00 PM PT / 6:00 PM ET. Investors and interested parties can access both the live audiocast and replay through the Events and Presentations section on Progyny's investor relations website at investors.progyny.com.

Progyny (PGNY) reported strong Q1 2025 financial results with record revenue of $324.0 million, up 16.5% year-over-year. The company's performance was driven by client and covered lives growth. Gross profit increased 21% to $75.8 million, with gross margin improving to 23.4%. Net income was $15.1 million ($0.17 per diluted share), while Adjusted EBITDA grew 15% to $57.8 million. The company expanded to 532 fertility and family building clients, up from 451 in Q1 2024. Based on strong Q1 performance, Progyny raised its full-year 2025 guidance, projecting revenue between $1.185-$1.235 billion. The company maintains a strong financial position with $256.1 million in cash and no debt.

Progyny (Nasdaq: PGNY), a global leader in women's health and family building, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:45 p.m. ET (1:45 p.m. PT) to discuss the results.

Participants can join the call using the following details:

• US participants: 1.866.825.7331
• International participants: 1.973.413.6106
• Passcode: 265484

An audio replay will be available through May 15, 2025. The event will also be accessible via live webcast from the company's investor relations website.